Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amlodipine/indapamide/perindopril - Servier

Drug Profile

Amlodipine/indapamide/perindopril - Servier

Alternative Names: Indapamide/perindopril/amlodipine; Perindopril/indapamide/amlodipine; S06593; Triplixam

Latest Information Update: 03 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Servier
  • Class Antihypertensives; Dihydropyridines; Indoles; Ischaemic heart disorder therapies; Small molecules; Sulfonamides
  • Mechanism of Action ACE inhibitors; Calcium channel antagonists; Thiazide-like diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Essential hypertension
  • Phase III Hypertension

Most Recent Events

  • 03 Jul 2019 Chemical structure information added
  • 05 Nov 2018 Launched for Essential hypertension in Russia (PO), prior to November 2018 (Servier Russia website, November 2018)
  • 21 Aug 2018 Serdia Pharmaceuticals completes a phase III trial in Hypertension in India (PO) (CTRI2017-09-009786)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top